Home / Market News / $VVOS
benzinga Corporate Catalyst Impact 65/100 ● neutral

Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M

Oct 19, 2026, 9:07 PM UTC · Primary ticker $VVOS

Vivos Therapeutics has acquired an 11% equity interest in SOD Sciences and a 50% co-ownership of SOD's 'Primed Cell for Chronic Disease' test. This strategic move, paid for with $12 million in Series C Convertible Preferred Stock, aims to expand Vivos's patient reach through a potential joint marketing arrangement with SOD and American Health Associates, targeting a large patient base in assisted living facilities.

Vivos Therapeutics has acquired an 11% fully diluted equity interest in SOD Sciences and a 50% co-ownership interest in SOD's 'Primed Cell for Chronic Disease' test. This transaction, valued at $12 million in preferred stock with no cash involved, is significant as it provides Vivos with a new diagnostic tool and potential access to a large patient population (325,000+ patients at 3,000 facilities) through a joint marketing arrangement with SOD and American Health Associates (AHA). This could be a long-term growth opportunity for Vivos, expanding its reach beyond its current focus on OSA treatment to include early detection of chronic diseases. The short-term impact is likely neutral to positive, as the deal is non-cash and opens up new avenues for revenue. However, the realization of the patient access is contingent on negotiating definitive agreements and approval from AHA's bankruptcy court, posing a key risk.

$VVOS positive Strategic acquisition and potential patient expansion
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.